Ceftazidime
As of the edition of 20 October 2026, Ceftazidime is a small molecule: marketed, first approved in 1985 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Fortaz
- First approved
- 11 June 1985 (FR)
- Approvals on record
- 20 in 7 regions
- Holder of the most recent approval
- Medochemie Limited; 8 holders in all
- Registered trials
- 53, 6 stopped early
- Disease areas
- Infections; Lungs and airways; Digestive system; Blood and lymph; Inherited and neonatal; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 24 | 13 | 6 | 3 |
| Phase 1 | 4 | 3 | 0 | 1 |
| Phase 2 | 8 | 7 | 0 | 0 |
| Phase 3 | 7 | 5 | 1 | 1 |
| Phase 4 | 10 | 6 | 1 | 1 |
| All trials | 53 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GSK | Earlier holder | 1985 to now |
| Pfizer | Applicant and Lead sponsor of trials | 2008 to now |
| B. Braun Medical | Later holder | 2011 to now |
| Pharmaceutical Associates | Acquired holder | 2022 to now |